118 related articles for article (PubMed ID: 34143695)
1. Mesothelin is Commonly Expressed in Pancreatic Adenocarcinoma but Unrelated to Cancer Aggressiveness.
Weidemann S; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Nahrstedt U; Jacobsen F; Bernreuther C; Simon R; Steurer S; Burandt E; Marx AH; Krech T; Clauditz TS; Jansen K
Cancer Invest; 2021 Oct; 39(9):711-720. PubMed ID: 34143695
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
3. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis.
Hassan R; Laszik ZG; Lerner M; Raffeld M; Postier R; Brackett D
Am J Clin Pathol; 2005 Dec; 124(6):838-45. PubMed ID: 16416732
[TBL] [Abstract][Full Text] [Related]
4. DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness.
Jansen K; Büscheck F; Moeller K; Kluth M; Hube-Magg C; Blessin NC; Perez D; Izbicki J; Neipp M; Mofid H; Daniels T; Nahrstedt U; Fraune C; Jacobsen F; Bernreuther C; Lebok P; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Marx A; Krech T; Clauditz T
PeerJ; 2021; 9():e11905. PubMed ID: 34414034
[TBL] [Abstract][Full Text] [Related]
5. Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma.
Dwertmann Rico S; Büscheck F; Dum D; Luebke AM; Kluth M; Hube-Magg C; Hinsch A; Höflmayer D; Perez D; Izbicki JR; Neipp M; Mofid H; Daniels T; Isbert C; Fraune C; Möller K; Menz A; Bernreuther C; Lebok P; Clauditz T; Sauter G; Uhlig R; Wilczak W; Simon R; Steurer S; Burandt E; Marx A; Krech T
Int J Immunopathol Pharmacol; 2022; 36():3946320221106504. PubMed ID: 35764407
[No Abstract] [Full Text] [Related]
6. Diagnostic value of IMP3 and mesothelin in differentiating pancreatic ductal adenocarcinoma from chronic pancreatitis.
Ibrahim DA; Abouhashem NS
Pathol Res Pract; 2016 Apr; 212(4):288-93. PubMed ID: 26874572
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma.
Einama T; Kamachi H; Nishihara H; Homma S; Kanno H; Takahashi K; Sasaki A; Tahara M; Okada K; Muraoka S; Kamiyama T; Matsuno Y; Ozaki M; Todo S
Pancreas; 2011 Nov; 40(8):1276-82. PubMed ID: 21775916
[TBL] [Abstract][Full Text] [Related]
8. Analysis of novel tumor markers in pancreatic and biliary carcinomas using tissue microarrays.
Swierczynski SL; Maitra A; Abraham SC; Iacobuzio-Donahue CA; Ashfaq R; Cameron JL; Schulick RD; Yeo CJ; Rahman A; Hinkle DA; Hruban RH; Argani P
Hum Pathol; 2004 Mar; 35(3):357-66. PubMed ID: 15017593
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin and GPR30 staining among a spectrum of pancreatic epithelial neoplasms.
Glass JP; Parasher G; Arias-Pulido H; Donohue R; Prossnitz ER; Cerilli LA
Int J Surg Pathol; 2011 Oct; 19(5):588-96. PubMed ID: 21632639
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin overexpression is a marker of tumor aggressiveness and is associated with reduced recurrence-free and overall survival in early-stage lung adenocarcinoma.
Kachala SS; Bograd AJ; Villena-Vargas J; Suzuki K; Servais EL; Kadota K; Chou J; Sima CS; Vertes E; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Clin Cancer Res; 2014 Feb; 20(4):1020-8. PubMed ID: 24334761
[TBL] [Abstract][Full Text] [Related]
11. Novel markers of pancreatic adenocarcinoma in fine-needle aspiration: mesothelin and prostate stem cell antigen labeling increases accuracy in cytologically borderline cases.
McCarthy DM; Maitra A; Argani P; Rader AE; Faigel DO; Van Heek NT; Hruban RH; Wilentz RE
Appl Immunohistochem Mol Morphol; 2003 Sep; 11(3):238-43. PubMed ID: 12966350
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors.
Weidemann S; Gagelmann P; Gorbokon N; Lennartz M; Menz A; Luebke AM; Kluth M; Hube-Magg C; Blessin NC; Fraune C; Möller K; Bernreuther C; Lebok P; Clauditz TS; Jacobsen F; Izbicki JR; Jansen K; Sauter G; Uhlig R; Wilczak W; Steurer S; Minner S; Burandt E; Krech RH; Dum D; Krech T; Marx AH; Simon R
Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917081
[TBL] [Abstract][Full Text] [Related]
13. Functional genomic mRNA profiling of a large cancer data base demonstrates mesothelin overexpression in a broad range of tumor types.
Lamberts LE; de Groot DJ; Bense RD; de Vries EG; Fehrmann RS
Oncotarget; 2015 Sep; 6(29):28164-72. PubMed ID: 26172299
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE).
Argani P; Iacobuzio-Donahue C; Ryu B; Rosty C; Goggins M; Wilentz RE; Murugesan SR; Leach SD; Jaffee E; Yeo CJ; Cameron JL; Kern SE; Hruban RH
Clin Cancer Res; 2001 Dec; 7(12):3862-8. PubMed ID: 11751476
[TBL] [Abstract][Full Text] [Related]
15. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.
Kendrick ZW; Firpo MA; Repko RC; Scaife CL; Adler DG; Boucher KM; Mulvihill SJ
HPB (Oxford); 2014 Jul; 16(7):670-6. PubMed ID: 24308545
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of mesothelin expression in colorectal cancer disclosed by area-specific four-point tissue microarrays.
Shiraishi T; Shinto E; Nearchou IP; Tsuda H; Kajiwara Y; Einama T; Caie PD; Kishi Y; Ueno H
Virchows Arch; 2020 Sep; 477(3):409-420. PubMed ID: 32107600
[TBL] [Abstract][Full Text] [Related]
17. A novel survival-based tissue microarray of pancreatic cancer validates MUC1 and mesothelin as biomarkers.
Winter JM; Tang LH; Klimstra DS; Brennan MF; Brody JR; Rocha FG; Jia X; Qin LX; D'Angelica MI; DeMatteo RP; Fong Y; Jarnagin WR; O'Reilly EM; Allen PJ
PLoS One; 2012; 7(7):e40157. PubMed ID: 22792233
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cells adenovirally-transduced with full-length mesothelin cDNA elicit mesothelin-specific cytotoxicity against pancreatic cancer cell lines in vitro.
Miyazawa M; Iwahashi M; Ojima T; Katsuda M; Nakamura M; Nakamori M; Ueda K; Naka T; Hayata K; Iida T; Yamaue H
Cancer Lett; 2011 Jun; 305(1):32-9. PubMed ID: 21397388
[TBL] [Abstract][Full Text] [Related]
20. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas.
Frierson HF; Moskaluk CA; Powell SM; Zhang H; Cerilli LA; Stoler MH; Cathro H; Hampton GM
Hum Pathol; 2003 Jun; 34(6):605-9. PubMed ID: 12827615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
